WallStSmart
PMCB

PharmaCyte Biotech Inc

NASDAQ: PMCB · HEALTHCARE · BIOTECHNOLOGY

$0.79
-3.50% today

Updated 2026-06-05

Market cap
$8.52M
P/E ratio
P/S ratio
12,904.41x
EPS (TTM)
$-0.89
Dividend yield
52W range
$1 – $2
Volume
0.2M

PharmaCyte Biotech Inc (PMCB) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20062007200820092010201120122013201420152016201720182019202020212022202320242025
Operating cash flow$-1.07M$-351596.00$-1.19M$-1.19M$-974057.00$-225232.00$-259289.00$-390426.00$-1.56M$-4.56M$-4.35M$-3.34M$-5.08M$-2.88M$-2.34M$-3.33M$-4.12M$-3.79M$-2.15M$-2.98M
Capital expenditures$7243.00$696519.00$21049.00$5080.00$0.00$5080.00$0.00$0.00$3.50M$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.00$4.00
Depreciation
Stock-based comp$984.00$17928.00$6.20M$2.10M$1.02M$1.53M$705678.00$748027.00$370829.00$77956.00$645406.00$674.00$478637.00
Free cash flow$-1.08M$-1.05M$-1.21M$-1.19M$-974057.00$-230312.00$-259289.00$-390426.00$-5.06M$-4.56M$-4.35M$-3.34M$-5.08M$-2.88M$-2.34M$-3.33M$-4.12M$-3.79M$-2.15M$-2.98M
Investing cash flow
Financing cash flow
Dividends paid$20116.00$22.46M$1.13M
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does PMCB generate?

PMCB produced $-2.98M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PMCB's balance sheet healthy?

PMCB holds $15.17M in cash and equivalents against — in long-term debt, on $51.89M of shareholder equity. That debt is best read against the cash flow the business throws off each year.